Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl.

Abstract

BACKGROUND AND OBJECTIVES\nFentanyl and other highly potent synthetic opioids\xa0are the leading cause of opioid overdose deaths in the United States.\n\n\nMETHODS\nThis study was\xa0an open-label, uncontrolled 12-week outpatient clinical trial to test the feasibility of a single-day induction onto extended-release buprenorphine (BXR) injection treatment for five adults (N\u2009=\u20095) with opioid use disorder using heroin-containing fentanyl. Participants were planned to receive three monthly BXR injections (300, 300, and 100\u2009mg).\n\n\nRESULTS\nAfter receiving 24\u2009mg sublingual buprenorphine (SL-BUP), all five participants received the BXR 300\u2009mg injection on the first day of induction. All five participants were retained for the full 3-month study period postinduction and received all three scheduled BXR injections.\n\n\nDISCUSSION AND CONCLUSION\nThis study provides preliminary evidence supporting the feasibility of inducting users of heroin-containing fentanyl onto BXR 300\u2009mg in a single day.\n\n\nSCIENTIFIC SIGNIFICANCE\nThe ability to administer a long-acting injection of BXR that assures therapeutic serum levels for a month on the first day of treatment contact is a promising development for the treatment of OUD.